Lerivon (Mianserin Hydrochloride)

Mianserin works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing serotonin receptors 5‑HT2 and 5‑HT3. The combined effect enhances both norepinephrine and serotonin neurotransmission, contributing to its antidepressant activity.

The dosage of Lerivon is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Physicians determine the appropriate starting dose and any subsequent adjustments, following local prescribing guidelines and patient‑specific factors.

The pregnancy category for Mianserin is listed as unknown, and limited data are available on its use during lactation. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing patients.

To order Lerivon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lerivon (Mianserin) belongs to the tetracyclic antidepressant class, which differs from selective serotonin reuptake inhibitors (SSRIs) by its broader receptor profile, including α2‑adrenergic antagonism. This may result in a distinct side‑effect spectrum, such as more sedation, but can be advantageous for patients who do not respond to SSRIs.

Lerivon should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lerivon is administered orally. The tablets (or other oral formulation) are taken with water, usually once daily or as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without consultation.

Serious adverse reactions to monitor include agranulocytosis (a marked drop in white blood cells), seizures, and cardiac arrhythmias. If any of these events occur, immediate medical attention is required and the medication should be discontinued under professional supervision.

Lerivon should be avoided in individuals with known hypersensitivity to Mianserin or any excipients, patients currently taking monoamine oxidase inhibitors, and those with uncontrolled severe cardiovascular disease. Caution is also advised for patients with a history of seizures or severe hepatic impairment.